The billionaire investor is being praised for launching a company that provides affordable medication.
A study found Israeli healthcare workers given fourth coronavirus vaccine shot at the height of Omicron were only marginally more protected against reinfection.
Harry and Meghan have been called "brave" by policy organization Global Justice Now for their signing of a letter marking 2 years of the COVID-19 pandemic.
However, truth Pharma told Newsweek in a statement that the additional $1 billion in payments was "an insult" due to the Sacklers' vast wealth.
How much longer must hardworking Americans ration their medications while drug companies make historic profits?
Biogen announced the Alzheimer's drug Aduhelm will now cost patients $28,200 per year after doctors were hesitant prescribing the treatment due to costs.
Califf said that his reasoning for returning to the FDA is public service, saying that he is "a 70-year-old person with nothing to gain."
Vyera Pharmaceuticals LLC and its parent company will pay $40 million over a 10-year period after increasing the price of Daraprim from $17.50 to $750 per pill.
Xavier Becerra pushed Trump to limit pharmaceutical price gouging. Now he's the one refusing to act.
He said vaccines enrich "the pockets of Big Pharma" and instead advocated for monoclonal antibody treatments—which cost about 62 times more.
The House Dems who helped the GOP kill reconciliation bill got more than $3 million from oil, pharma: two industries possibly targeted by the legislation.
As a lifelong Democrat, I'm proud to see Congress on the verge of passing this historic legislation. I understand the need to pay for these critical investments. But there are other ways to fund much needed reforms—ways that don't make drugs even more expensive.
Congress should enact regulations to loosen the grip the pharmaceutical industry has on America's doctors.
Organic and non-GMO ingredients should be used whenever possible, and should be sourced responsibly and ethically with stringent policies in place.
Decades after Bernie Sanders first ran bus trips to Canada, President Biden has a bipartisan opportunity to end drugmakers' ability to lock Americans out of lower-priced medicine.
Biden said he'd offer a public option for health insurance. He didn't—leaving states on their own to fight some of the nation's largest, richest and most politically organized businesses.
People in the businesses of health and wellness have every reason to launch new and bigger efforts to reach consumers across every platform available, providing engaging, credible content that stands out amid the noise.
President Joe Biden caved to political pressure from congressional Democrats on Wednesday, announcing that he plans to back a proposal to waive intellectual property rights for COVID-19 vaccines.
In developing its vaccine, Pfizer was doing what the private sector does best: thrive under pressure and respond to market demands as no government agency can.
In the weeks before and after the Montana Republican threw his weight behind the proposal, he received a total of $18,500 from seven different Big Pharma political action committees.
Rep. Rashida Tlaib (D-Mich.) accused the CEO of drug company Teva of pretending to "look like you give a shit about sick people" while making ever-increasing profits during House testimony on Wednesday.
The pharmaceutical industry is donating large amounts to Biden's campaign but there are doubts he'll deliver on prescription drug prices.
Through aggressive promotion and selective media leaks to inflate their stock prices, pharmaceutical company executives and insiders are profiteering from the pandemic. Congress must stop them.
Americans have good reason to be skeptical that Big Pharma will be our savior in this crisis—unless our fellow Republicans and Democrats in Congress intervene.
There is growing bipartisan agreement that we need to bring pharmaceutical production back home. But one enormous hurdle remains.
In his weekly round-up of business and economic news, Newsweek editorial director Hank Gilman gives the lowdown on AOC vs. Cramer, pharma shortages and the future of shopping
Researchers have compared the profit margins of America's drug companies, finding they are comparable with technology companies and higher than most industries.
A drug looking to relieve symptoms of the autoimmune disease lupus by blocking receptors for the immune protein has just completed its third clinical trial.
Following major recalls of Chinese-manufactured medication that contained carcinogenic ingredients, lawmakers expressed their alarm, and sometimes disbelief, at the FDA's inability to regulate foreign suppliers at a Tuesday hearing.